Software de análisis automático basado en IA de imágenes de resonancia magnética cardiaca

Referencia:TOKR20240913001
Title

A Korean startup developed AI based cardiac MR image automatic analysis software is seeking for commercial or R and D cooperation partners

Abstract

A Korean startup established by cardio radiologists has developed AI-based automatic cardiac MR image analysis solution. This solution provides fully automated analysis of cardiac MR images and reduces analysis and diagnosing time by 5 times. The company is looking for partners either commercial partners or R and D partners.

Description

According to WHO, cardiovascular disease is the leading cause of death worldwide, killing 17.8 million people each year. For diagnosis of this fatal disease, cardiac MR scanning is normally used, however, the lack of cardio-radiologists and complex and long analysis times are factors that hinder timely treatment.

To address this issue, a group of Korean cardio radiologist established a company in 2019 and have developed an automated AI-based cardiac MR image analysis solution. This solution is an AI-based reading and reporting software that automatically analyses and accurately quantifies complex cardiovascular MR images. It is designed as a medical device type software for radiologists, cardiologists and researchers to make faster and more accurate diagnostic decisions as prompt diagnosis and treatment is of utmost importance.

Key features of the solution are diagnostic MR finding report, visualization of CMR (Cardiac Magnetic Resonance) images, quantitative mapping analysis, cardiac function analysis, strain and wall analysis, tissue characterization, phase contrast flow analysis, perfusion analysis, and so on. For clinically, the solution provides precision non-invasive diagnosis, prognostic insights for cardiac health, pioneering diagnostic recommendations, enhanced cardiac imaging, and user-focused diagnostic experience.

Moreover, as Korean startup is comprised of researchers who can support and assist medical staff who are interested in using AI solution to further their research studies, the company can provide value added professional services along with the software solution.

The solution has been approved by USA FDA, Korea FDA, Taiwan FDA, Thailand FDA and Malaysia FDA, and the company has partnered with major medical device distributors in above countries.

The Korean startup seeks partners of medical device distributors or medical imaging platform companies under commercial agreement with technical assistance. Also, the company is interested in research and development cooperation with MR scanner manufacturers or PACS (Picture Archiving Communication System) integrators that are interested in advancing analysis software that can be synched to their solutions.
Advantages and innovation
The solution provides fully automated analysis and clinical optimisation of cardiac MR images, and has advantages as follows;
- Time-saving: achieving super high-speed with high advanced AI technology (5 times faster than human analysis)
- Reliability: meticulously checked by certified medical professionals
- Full-automation: fully automatic from analysis to report
- Standardization: provide Z-score for standardization of analysis result

In addition, Cardiac MRI related clinical researchers have benefits by using this solution such as easy data management with automatic labelling, automatic analysis and statistics of Radiomics, and easy conducting advanced tissue characterization research with synthetic LGE (Late Gadolinium Enhancement) images.

Si tiene interés en la oportunidad tecnológica, por favor cumplimente el siguiente formulario.

All fields are mandatory. By filling this form I accept that my data are stored in the Enterprise Europe Network database

 

Name

Company

Email

Subject TOKR20240913001

 

a) In what type of technology, business or research collaboration are you interested in? (max. 600 characters)

 

b) What type of further information do you need? (max. 600 characters)

 

 

c) Presentation of the Interested Company? (max. 600 characters)